Jeil Pharm (002620) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jeil Pharm (002620) has a cash flow conversion efficiency ratio of 0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩447.08 Million ≈ $302.98K USD) by net assets (₩475.12 Billion ≈ $321.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 002620 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Jeil Pharm - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Jeil Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jeil Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jeil Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mastech Holdings Inc
NYSE MKT:MHH
|
0.074x |
|
American Vanguard Corporation
NYSE:AVD
|
-0.187x |
|
Investec plc
LSE:INVR
|
-0.102x |
|
Tradetool Auto Co Ltd
TWO:3685
|
0.040x |
|
Al-Salam Real Estate Investment Trust
KLSE:5269
|
0.068x |
|
Mordechai Aviv Taasiot Beniyah 1973 Ltd
TA:AVIV
|
-0.083x |
|
Complex Micro Interconnection Co. Ltd.
TW:6835
|
-0.011x |
|
Falcon Metals Ltd
AU:FAL
|
-0.177x |
Annual Cash Flow Conversion Efficiency for Jeil Pharm (2011–2025)
The table below shows the annual cash flow conversion efficiency of Jeil Pharm from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Jeil Pharm market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩469.12 Billion ≈ $317.91 Million |
₩390.26 Million ≈ $264.47K |
0.001x | -91.99% |
| 2024-12-31 | ₩437.40 Billion ≈ $296.42 Million |
₩4.54 Billion ≈ $3.08 Million |
0.010x | +194.59% |
| 2023-12-31 | ₩402.19 Billion ≈ $272.56 Million |
₩-4.42 Billion ≈ $-2.99 Million |
-0.011x | +77.84% |
| 2022-12-31 | ₩419.79 Billion ≈ $284.49 Million |
₩-20.80 Billion ≈ $-14.10 Million |
-0.050x | -284.97% |
| 2021-12-31 | ₩500.31 Billion ≈ $339.06 Million |
₩13.40 Billion ≈ $9.08 Million |
0.027x | +156.50% |
| 2020-12-31 | ₩499.28 Billion ≈ $338.36 Million |
₩-23.67 Billion ≈ $-16.04 Million |
-0.047x | -190.82% |
| 2019-12-31 | ₩483.04 Billion ≈ $327.35 Million |
₩25.22 Billion ≈ $17.09 Million |
0.052x | +996.58% |
| 2018-12-31 | ₩589.58 Billion ≈ $399.55 Million |
₩-3.43 Billion ≈ $-2.33 Million |
-0.006x | -116.75% |
| 2017-12-31 | ₩170.44 Billion ≈ $115.50 Million |
₩5.92 Billion ≈ $4.01 Million |
0.035x | -22.85% |
| 2016-12-31 | ₩252.08 Billion ≈ $170.83 Million |
₩11.36 Billion ≈ $7.70 Million |
0.045x | +296.38% |
| 2015-12-31 | ₩241.39 Billion ≈ $163.59 Million |
₩2.74 Billion ≈ $1.86 Million |
0.011x | +169.58% |
| 2012-12-31 | ₩241.41 Billion ≈ $163.60 Million |
₩-3.94 Billion ≈ $-2.67 Million |
-0.016x | -116.00% |
| 2011-12-31 | ₩231.40 Billion ≈ $156.81 Million |
₩23.63 Billion ≈ $16.01 Million |
0.102x | -- |
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more